Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A, Bonnet M, Rubinstein E, Pouget JP, Opolon P, Maigne L, Miot-Noirault E, Chezal JM, Boucheix C, Degoul F. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer Oncotarget. 2017 Mar 28;8(13): 22034-22047. doi: 10.18632/ oncotarget.15787.


Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget. 2017 Feb 24. doi: 10.18632/ oncotarget.15715. [Epub ahead of print]


Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Pouget JP, Bardiès M. Realistic multi-cellular dosimetry for 177Lu-labelled antibodies: model and application. Phys Med Biol. 2016 Sep 12;61(19):6935-6952. [Epub ahead of print]


Renard D, Collombier L, Castelli C, Pouget JP, Kotzki PO, Boudousq V. In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8. BMC Neurol. 2016 Jul 13;16:100.


Paillas S, Ladjohounlou R, Lozza C, Pichard A, Deshayes E, Jarlier M, Sevestre S, Le Blay M, Boudousq V, Sosabowski J, Chardes T, Teulon I, Mairs R, Pouget JP. Localized irradiation of cell membrane by Auger electrons is cytotoxic through oxidative stress-mediated non-targeted effects. Antioxid Redox Signal. 2016 May 25. [Epub ahead of print]


Sibille L, Chambert B, Alonso S, Barrau C, D'Estanque E, Al Tabaa Y, Collombier L, Demattei C, Kotzki PO, Boudousq V. Impact of the Adaptive Statistical iterative Reconstruction (ASiR) technique on radiation dose and image quality in bone SPECT/CT. J Nucl Med. 2016 Mar 24. pii: jnumed.115.164772. [Epub ahead of print]


Arnaud FX, Paillas S, Pouget JP, Incerti S, Bardiès M, Bordage MC. Complex cell geometry and sources distribution model for Monte Carlo single cell dosimetry with iodine 125 radioimmunotherapy. Nuclear Inst. and Methods in Physics Research, B 1: 227-233.


Pouget JP, Lozza C, Deshayes E, Boudousq V and Navarro-Teulon I, Introduction to radiobiology of targeted radionuclide radiotherapy. Front Med (Lausanne). 2015 Mar 17;2:12.  eCollection 2015. Review.


Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS One. 2015 Jun 11;10(6):e0128816.  eCollection 2015.

Piron B, Paillas S, Boudousq V, Pelegrin A, Bascoul-Mollevi C, Chouin N, Navarro-Teulon I and Pouget JP, DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy. Nucl Med Biol 2014. 41 Suppl: p. e75-83.

Perrier M, Busson M, Massasso G, Long J, Boudousq V, Pouget JP, Peyrottes S, Perigaud C, Porredon-Guarch C, de Lapuente J, Borras M, Larionova J and Guari Y, (2)(0)(1)Tl(+)-labelled Prussian blue nanoparticles as contrast agents for SPECT scintigraphy. Nanoscale 2014. 6(22): p. 13425-9.

Nesterov SV, Deshayes E, Sciagra R, Settimo L, Declerck JM, Pan XB, Yoshinaga K, Katoh C, Slomka PJ, Germano G, Han C, Aalto V, Alessio AM, Ficaro EP, Lee BC, Nekolla SG, Gwet KL, deKemp RA, Klein R, Dickson J, Case JA, Bateman T, Prior JO, and Knuuti JM, Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 Study. JACC Cardiovasc Imaging 2014. 7(11): p. 1119-27.

Kersual N, Garambois V, Chardes T, Pouget JP, Salhi I, Bascoul-Mollevi C, Bibeau F, Busson M, Vie H, Clemenceau B, Behrens CK, Estupina P, Pelegrin A and Navarro-Teulon I, The human Mullerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. MAbs 2014. 6(5): p. 1314-26.

Gardette M, Viallard C, Paillas S, Guerquin-Kern JL, Papon J, Moins N, Labarre P, Desbois N, Wong-Wah-Chung P, Palle S, Wu TD, Pouget JP, Miot-Noirault E, Chezal JM and Degoul F, Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Invest New Drugs 2014. 32(4): p. 587-97.

Elgqvist J, Frost S, Pouget JP and Albertsson P, The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol 2014. 3: p. 324.

Renard D, Vandenberghe R, Collombier L, Kotzki PO, Pouget JP and Boudousq V, Glucose metabolism in nine patients with probable sporadic Creutzfeldt-Jakob disease: FDG-PET study using SPM and individual patient analysis. J Neurol 2013. 260(12): p. 3055-64.

Paillas S, Boudousq V, Piron B, Kersual N, Bardies M, Chouin N, Bascoul-Mollevi C, Arnaud FX, Pelegrin A, Navarro-Teulon I and Pouget JP, Apoptosis and p53 are not involved in the anti-tumor efficacy of (1)(2)(5)I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol 2013. 40(4): p. 471-80.

Ortega C, Herbet A, Richard S, Kersual N, Costa N, Pelegrin A, Ducancel F, Couraud JY, Navarro-Teulon I and Boquet D, High level prokaryotic expression of anti-Mullerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. J Immunol Methods 2013. 387(1-2): p. 11-20.

Navarro-Teulon I, Lozza C, Pelegrin A, Vives E and Pouget JP, General overview of radioimmunotherapy of solid tumors. Immunotherapy 2013. 5(5): p. 467-87.

Marre F, Sibille L, Nalda E, Kotzki PO and Boudousq V, (18)F-FDG PET/CT imaging of critical ischemia in the diabetic foot. Clin Nucl Med 2013. 38(4): p. 269-71.

Lozza C, Navarro-Teulon I, Pelegrin A, Pouget JP and Vives E, Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers. Front Oncol 2013. 3: p. 247.

Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G and Seve P, 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med 2013. 38(1): p. e50-2.

Deshayes E, Kraeber-Bodere F, Vuillez JP, Bardies M, Teulon I and Pouget JP, Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy 2013. 5(12): p. 1283-6.

Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pelegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I and Pouget JP, Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One 2013. 8(7): p. e69613.

Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A and Azria D, Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol 2011. 8(12): p. 720-34.


Nalda E, Mahadea KK, Demattei C, Kotzki PO, Pouget JP and Boudousq V, Assessment of the Stratos, a new pencil-beam bone densitometer: dosimetry, precision, and cross calibration. J Clin Densitom 2011. 14(4): p. 395-406.

Ladjemi MZ, Jacot W, Pelegrin A and Navarro-Teulon I, [Anti-HER2 vaccines: The HER2 immunotargeting future?]. Pathol Biol (Paris) 2011. 59(3): p. 173-82.

Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A and Navarro-Teulon I, Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res 2011. 13(1): p. R17.

Colombo PE, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P and Vert M, Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Gynecol Oncol 2011. 122(3): p. 632-40.

Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A and Azria D, Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 2010. 21(1): p. 98-103.

Ladjemi MZ, Jacot W, Chardes T, Pelegrin A and Navarro-Teulon I, Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010. 59(9): p. 1295-312.

Boudousq V, Ricaud S, Garambois V, Bascoul-Mollevi C, Boutaleb S, Busson M, Quenet F, Colombo PE, Bardies M, Kotzki PO, Navarro-Teulon I, Pelegrin A and Pouget JP, Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med 2010. 51(11): p. 1748-55.

Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pelegrin M, Navarro-Teulon I, Pelegrin A and Pouget JP, Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009. 50(12): p. 2033-41.

Boutaleb S, Pouget JP, Hindorf C, Pelegrin A, Barbet J, Kotzki PO, Bardies M and  Impact of Mouse Model on Preclinical Dosimetry in Targeted Radionuclide Therapy. Proceedings of the IEEE 2009. 97: p. 2076-2085.

Boudousq V, Nalda E, Jaegler E, Thomas E, Dinten JM, Collombier L, Boisson N, Demattei C and Kotzki PO, Data acquisition analysis for femoral morphometric X-ray absorptiometry. J Clin Densitom 2009. 12(2): p. 177-85.

Alvarez-Rueda N, Ladjemi MZ, Behar G, Corgnac S, Pugniere M, Roquet F, Bascoul-Mollevi C, Baty D, Pelegrin A and Navarro-Teulon I, A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine 2009. 27(35): p. 4826-33.

Pouget JP, Santoro L, Raymond L, Chouin N, Bardies M, Bascoul-Mollevi C, Huguet H, Azria D, Kotzki PO, Pelegrin M, Vives E and Pelegrin A, Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res 2008. 170(2): p. 192-200.


Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I and Cliby WA, Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 2008. 108(1): p. 141-8.



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Conception : ID Alizés